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Highlights 
 
• Bioengineered nisin variants and essential oils were tested for inactivation of C. 
sakazakii and E. coli O157:H7. 
• Nisin variant and essential oil combinations caused extended lag phases of growth 
compared to nisin A-essential oil combinations. 
• Nisin variant-carvacrol combinations significantly reduced C. sakazakii and E. coli 
O157:H7 compared to nisin A-carvacrol treatment. 
• Nisin variant-carvacrol combinations caused complete inactivation of E. coli O157:H7 
in apple juice compared to nisin A-carvacrol treatment. 
• Commercial Nisaplin and citric acid combinations also resulted in complete 
inactivation of C. sakazakii in infant formula. 
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Abstract 23 
 24 
Cronobacter sakazakii and Escherichia coli O157:H7 are well known food-25 
borne pathogens that can cause severe disease. The identification of new 26 
alternatives to heating to control these pathogens in foods, while reducing the 27 
impact on organoleptic properties and nutritional value, is highly desirable. In this 28 
study, nisin and its bioengineered variants, nisin V and nisin S29A, are used alone, or 29 
in combination with plant essential oils (thymol, carvacrol and trans-30 
cinnamaldehyde) or citric acid, with a view to controlling C. sakazakii and E. coli 31 
O157:H7 in laboratory-based assays and model food systems. The use of nisin 32 
variants (30 µM) with low concentrations of thymol (0.015%), carvacrol (0.03%) and 33 
trans-cinnamaldehyde (0.035%) resulted in extended lag phases of growth compared 34 
to those for corresponding nisin A-essential oil combinations. Furthermore, nisin 35 
variants (60 µM) used in combination with carvacrol (0.03%) significantly reduced 36 
viable counts of E. coli O157:H7 (3-log) and C. sakazakii (4-log) compared to nisin A-37 
carvacrol treatment. Importantly, this increased effectiveness translated into food. 38 
More specifically, sub-inhibitory concentrations of nisin variants and carvacrol 39 
caused complete inactivation of E. coli O157:H7 in apple juice within 3 hours at room 40 
temperature compared to that of the equivalent nisin A combination. Furthermore, 41 
combinations of commercial Nisaplin and the food additive citric acid reduced C. 42 
sakazakii numbers markedly in infant formula within the same 3 h period. These 43 
results highlight the potential benefits of combining nisin and variants thereof with 44 
carvacrol and/or citric acid for the inhibition of Gram negative food-borne 45 
pathogens.  46 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3
 47 
Keywords 48 
 49 
C. sakazakii, E. coli O157:H7, Nisin, Essential oils, Apple juice, Infant formula milk 50 
 51 
1. Introduction 52 
 53 
Cronobacter sakazakii and Escherichia coli O157:H7 are both significant Gram 54 
negative foodborne pathogens. They have garnered special notoriety because of 55 
their association with life-threatening diseases. Their presence in food poses a 56 
serious health risk for consumers and is a safety concern for the food industry. 57 
Enterohaemorrhagic E. coli O157:H7 can cause devastating and severe illness such as 58 
haemorrhagic colitis and haemolytic uremic syndrome. Approximately 10-15% of E. 59 
coli O157:H7 infections result in haemolytic uremic syndrome, causing acute renal 60 
failure in children and 3-5% of cases are fatal (Ho et al., 2013). There have been 61 
several outbreaks associated with the consumption of food contaminated with E. coli 62 
O157:H7 (Vidovic and Korber, 2014). Similarly, C. sakazakii can cause a range of 63 
serious neonatal infections such as meningitis, septicaemia and enteritis (Drudy et 64 
al., 2006; Gurtler et al., 2005). Several disease outbreaks have been associated with 65 
the contamination of powdered infant formula milk (CDC, 2002; Iversen and 66 
Forsythe, 2004). C. sakazakii has a high mortality rate of 40-80%, and death can 67 
occur within hours (Bowen and Braden, 2006; Norberg et al., 2012). Infection may 68 
also result in severe sequelae such as hydrocephalus, quadriplegia and retarded 69 
neural development among survivors (Forsythe, 2005). 70 
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 Heat treatments and chemical preservatives are commonly used as hurdles 71 
to control foodborne pathogens and spoilage bacteria. However, these processes 72 
may have undesirable effects, such as altering the nutritional and sensory properties 73 
of the food.  Furthermore, there has been an increasing consumer demand for 74 
additive-free, minimally processed foods, while still maintaining adequate 75 
microbiological safety and stability. Therefore, the use of natural antimicrobials as 76 
food preservatives has been the focus of ever-increasing attention. Among these 77 
natural alternatives are bacteriocins.  Bacteriocins are ribosomally synthesised, post-78 
translationally modified peptides that are produced by bacteria and which are active 79 
against other bacteria. They can have a narrow range of activity within their own 80 
species or a broad spectrum of activity across genera (Cotter et al., 2005). Although 81 
there are numerous bacteriocins with food preservation potential, only nisin, 82 
produced by Lactococcus lactis, is used extensively. Nisin A has been assigned to the 83 
lantibiotic class of bacteriocins due to the presence of unusual amino acids that arise 84 
due to the post-translational modification of serine and threonine residues 85 
ultimately leading to the formation of lanthionine and β-methyllanthionine ring 86 
structures, respectively (Bierbaum and Sahl, 2009; Sahl et al., 1995). Nisin A is used 87 
in over 50 countries worldwide and has been approved for use by both the EU (E234) 88 
and the Food and Drug Administration (FDA) (Delves-Broughton, 1990). Nisin A 89 
functions through a unique dual mode of action. It binds to lipid II, an essential 90 
precursor to cell wall biosynthesis, while also inserting itself into the bacterial cell 91 
membrane. This facilitates pore formation and ultimately leads to the loss of solutes 92 
from the bacterial cell resulting in cell death (Wiedemann et al., 2004; Wiedemann 93 
et al., 2001).  94 
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The gene-encoded nature of nisin A allows for its manipulation in order to 95 
modify its biological and physical properties. Indeed, recent research has shown that 96 
bioengineering of nisin A can result in variants with greater potency towards food-97 
borne pathogens (Field et al., 2015b). One particular variant, M21V (nisin V), has 98 
shown enhanced activity towards several Gram positive pathogens, including Listeria 99 
monocytogenes, compared to that of nisin A (Field et al., 2010). Although nisin A is 100 
effective against Gram positive bacteria such as Staphylococci, Bacilli and Clostridia 101 
(Bierbaum and Sahl, 2009; Sobrino-López and Martín-Belloso, 2008), Gram negative 102 
bacteria are generally not as sensitive. However, novel variants, such as nisin S29A 103 
and S29G, with enhanced activity towards Gram negative food-associated pathogens 104 
exist (Field et al., 2012). Nisin A may also be effective against Gram negatives if their 105 
outer membrane is destabilized with chelating agents (Stevens et al., 1991). 106 
Membrane disruption/permeabilisation is also thought to be the basis for the 107 
observation that nisin, when combined with the phenolic compounds carvacrol and 108 
thymol which possess membrane permeability properties, exhibit enhanced activity 109 
against Gram negative bacteria by permitting nisin to pass through the protective 110 
outer membrane (Helander et al., 1998). In fact, there are several studies 111 
demonstrating that nisin and essential oil combinations exhibit enhanced inhibitory 112 
effects against both Gram positive and Gram negative bacteria (Ettayebi et al., 2000; 113 
Olasupo et al., 2003; Olasupo et al., 2004; Periago and Moezelaar, 2001; Pol and 114 
Smid, 1999; Yuste and Fung, 2004). More recently, nisin-containing semi-purified 115 
preparations in combination with carvacrol and trans-cinnamaldehyde were 116 
established to more effectively inhibit L. monocytogenes than either treatment alone 117 
(Field et al., 2015a). 118 
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The aim of this study was to evaluate the antimicrobial activity of nisin A, or the 119 
bioengineered nisin derivatives nisin V and S29A, when combined with the 120 
essential oils, thymol, carvacrol or trans-cinnamaldehyde, or citric acid against 121 
the Gram negative pathogens C. sakazakii NCTC 8155::p16Slux-Phelp or E. coli 122 
O157:H7 TUV 93-0::p16Slux-Phelp.  123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
2. Materials and Methods 132 
 133 
2.1 Bacterial strains and growth conditions 134 
 135 
The nisin producing strains and lux-tagged bacterial strains used in this study 136 
are listed in Table 1. L. lactis strains were grown in M17 broth (Oxoid) supplemented 137 
with 0.5% glucose (GM17) or GM17 agar at 30°C. E. coli and C. sakazakii cultures 138 
were grown in Luria-Bertani (LB) broth or agar at 37°C. When required, antibiotics 139 
were used where indicated at the following concentrations: chloramphenicol at 10 140 
μg ml
-1
 for L. lactis and erythromycin at 500 μg ml
-1
 for E. coli and C. sakazakii. Stock 141 
solutions of thymol (Sigma) were prepared at 50 mg ml
-1
 in 50% ethanol and stored 142 
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at -20°C. Carvacrol and trans-cinnamaldehyde (Sigma) were diluted from stock 143 
(0.976 g ml
-1
 and 1.05 g ml
-1
, respectively) in 50% ethanol to the desired 144 
concentration. Stock solutions of Nisaplin (Sigma) and citric acid (Sigma) were 145 
prepared at 100 mg ml
-1
 and 500 mM in sdH20, respectively, filter sterilised and 146 
diluted to the desired concentration. In all experiments, the concentration of ethanol 147 
did not exceed 2% (vol/vol). 148 
 149 
2.2 Nisin purification 150 
 151 
Purification of wild type nisin A and nisin derivatives were carried out as 152 
described previously (Field et al., 2010). Briefly, overnight cultures of nisin producing 153 
strains were grown in GM17 broth at 30°C and were subsequently inoculated into 154 
two litres of purified TY broth at 1% and incubated overnight at 30°C. The culture 155 
was centrifuged at 7,000 r.p.m. for 20 minutes and the supernatant retained. The 156 
cell pellet was resuspended in 300ml of 70% isopropanol 0.1% TFA and magnetically 157 
stirred for 3 h at room temperature. Cell debris was removed by centrifugation at 158 
7,000 r.p.m. for 20 minutes and the supernatant retained. The supernatant was 159 
applied to a 60 g Amberlite bead (Sigma) column, which was subsequently washed 160 
with 500 ml of 30% ethanol and the inhibitory activity eluted in 500 ml of 70% 161 
isopropanol 0.1% trifluoroacetic acid (TFA). The isopropanol was evaporated off 162 
using a rotary evaporator (Buchi) to a volume of 160ml and the sample pH adjusted 163 
to approximately 4.2. The sample was applied to a 10g (60ml) Varian C-18 Bond Elut 164 
Column previously pre-equilibrated with HPLC water and methanol. The column was 165 
washed with 120 ml of 30% ethanol and the inhibitory activity eluted in 60 ml of 70% 166 
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isopropanol 0.1% TFA. Six millilitres of the lantibiotic preparation was concentrated 167 
to 1 ml through the removal of the isopropanol by rotary evaporation and applied to 168 
a Phenomenex C12 reverse-phase (RP)-HPLC column, previously equilibrated with 169 
25% isopropanol 0.1% TFA. The column was then developed in a gradient of 30% 170 
isopropanol 0.1% TFA to 60% isopropanol 0.1% TFA from 10 to 45 minutes at a flow 171 
rate of 2.1 ml min
-1
. Fractions containing nisin A and nisin derivative peptides were 172 
collected and subjected to Mass Spectrometry with a Shimadzu Biotech MALDI-TOF 173 
Mass Spectrometer (AXIMA-CFR plus model). 174 
 175 
2.3 Mass spectrometry 176 
 177 
For colony mass spectrometry analysis, bacteria were collected with sterile 178 
plastic loops and mixed with 50 ml of 70% isopropanol adjusted to pH2 with HCl. The 179 
suspension was vortexed, centrifuged at 14,000 r.p.m. for 2 minutes and the 180 
supernatant retained for analysis. Mass spectrometry in all cases was performed 181 
with an Axima CFR plus matrix-assisted laser desorption/ionisation time-of-flight 182 
(MALDI TOF) mass spectrometer (Shimadzu Biotech, Manchester, UK.) A 0.5 μl 183 
aliquot of matrix solution (alpha-cyano-4-hydroxy cinnamic acid (CHCA), 10mg ml
-1
 in 184 
50% acetonitrile-0.1% (v/v) trifluoroacetic acid) was placed onto the target and left 185 
for 1-2 minutes before being removed. The residual solution was then air dried and 186 
the sample solution (re-suspended lyophilized powder or colony mass spectrometry 187 
supernatant) was positioned onto the pre-coated sample spot. Matrix solution (0.5 188 
ml) was added to the sample and allowed to air dry. The sample was subsequently 189 
analysed in positive-ion reflectron mode. 190 
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 191 
 192 
2.4 Minimum inhibitory concentration (MIC) assays 193 
 194 
The MIC of nisin peptides against Gram negative organisms were carried out 195 
in triplicate in microtitre plates as previously described (Field et al., 2010). Briefly, 196 
96-well microtitre plates were pre-treated with phosphate buffered saline (PBS) 197 
containing 1% (w/v) bovine serum albumin (BSA) and subsequently incubated at 198 
37°C for 30 minutes. Wells were washed with PBS and allowed to air-dry before the 199 
addition of 100 μl double-strength LB broth. Gram negative strains were grown 200 
overnight in LB broth at 37°C, subcultured into fresh LB broth and grown to mid-201 
logarithmic phase (OD600nm ~ 0.5). The cells were harvested by centrifugation, 202 
washed with 10 mM SPB at pH 7.4 and diluted to 1 ×10
5 
cfu ml
-1
 in 10 mM SPB pH 203 
7.4. Nisin and nisin derivative purified peptides were resuspended in double-204 
strength LB broth to a stock concentration of 60 μM. Peptides were then adjusted to 205 
a starting concentration of 15 μM and 2-fold dilutions of the nisin peptides were 206 
carried out in the 96-well plates. Target organisms were added and plates were 207 
incubated at room temperature overnight (~16 h). The MIC was taken as the lowest 208 
concentration of peptide at which growth was inhibited.  The MIC of essential oils 209 
against Gram negative strains were carried out as above but with minor variations; 210 
BSA treatment of 96-well plates were not required and essential oils were diluted to 211 
a starting concentration of 2 mg ml
-1
 for serial dilution of thymol, carvacrol and 212 
trans-cinnamaldehyde. 213 
 214 
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2.5 Growth/Kill assays 215 
 216 
Growth and kill assays were carried out using representative strains as a 217 
consequence of the limited amount of pure material available. For growth assays, 218 
overnight cultures of target strains were harvested by centrifugation, washed in 10 219 
mM SPB pH 7.4 and transferred (1 × 10
7
 cfu ml
-1
 in a 1.0 ml volume) into LB broth 220 
containing nisin purified peptide alone and in combination with one of the essential 221 
oils being investigated. A volume of 200 μl was transferred to a 96-well plate 222 
(Genetix) and cell growth was measured spectrophotometrically using a Spectra Max 223 
340 spectrophotometer (Molecular Devices, Sunnyvale, California) for 24 h. For kill 224 
assays, overnight cultures of target strains were again harvested by centrifugation, 225 
washed in 10 mM SPB pH 7.4 and transferred (1 × 10
7
 cfu ml
-1
 in a 0.5 ml volume) 226 
into LB broth containing nisin purified peptide alone and in combination with one of 227 
the essential oils. Samples were incubated for 3 h at room temperature before serial 228 
dilution and enumeration on LB agar plates. All experiments were carried out in 229 
triplicate. 230 
 231 
2.6 Infant milk formula trial 232 
 233 
Commercially available powdered infant formula (PIF) (Aptamil First Milk) 234 
was prepared according to manufacturer’s instructions and brought to room 235 
temperature. The pH of the reconstituted PIF was 6.8 as determined with a pH 236 
meter. An overnight culture of C. sakazakii NCTC 8155::p16Slux-Phelp was washed in 237 
10 mM SPB pH 7.4, diluted and inoculated into reconstituted PIF at a final 238 
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concentration of 1 × 10
5
 cfu ml
-1
. PIF samples were treated with 201.12 μg ml
-1
 (60 239 
μM) of nisin A, nisin V or nisin S29A, alone and in combination with carvacrol at a 240 
concentration of 300 μg ml
-1
. Samples with carvacrol alone, C. sakazakii NCTC 241 
8155::p16Slux-Phelp alone and PIF alone served as controls. Samples were incubated 242 
at room temperature and C. sakazakii NCTC 8155::p16Slux-Phelp levels were 243 
determined through serial dilution and plate count technique on Druggan-Forsythe-244 
Iversen (DFI) agar at 3 h. Where Nisaplin (Sigma), and citric acid (Sigma) were 245 
employed, concentrations of 10 mg ml
-1
 and 30 mM were used, respectively. 246 
Nisaplin (containing 2.5% nisin) was resuspended in sdH2O and filter sterilised before 247 
use. The addition of citric acid did not significantly alter the pH of PIF. All 248 
experiments were carried out in triplicate.  249 
 250 
2.7 Apple juice trial 251 
 252 
Commercially available apple juice was brought to room temperature, 253 
filtered and the pH determined as 3.2 with a pH meter. An overnight culture of E. coli 254 
O157:H7 TUV 93-0::p16Slux-Phelp was washed in 10 mM SPB pH 7.4, diluted and 255 
inoculated into the apple juice at a final concentration of 1 × 10
5
 cfu ml
-1
. Apple juice 256 
samples were treated with 100.56 μg ml
-1
 (30μM) of nisin A, nisin V or nisin S29A, 257 
alone and in combination with carvacrol at a concentration of 75 μg ml
-1
. Samples 258 
with carvacrol alone, E. coli O157:H7 TUV 93-0::p16Slux-Phelp alone and apple juice 259 
alone served as controls.  Samples were incubated at room temperature and E. coli 260 
O157:H7 TUV 93-0::p16Slux-Phelp levels were determined through serial dilution and 261 
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plate count technique on Sorbitol MacConkey agar at 3 h. All experiments were 262 
carried out in triplicate. 263 
 264 
2.8 Statistical analysis 265 
 266 
CFU data was transformed to log10 prior to analysis using the statistical software 267 
package GraphPad Prism 6. All comparisons were based on the mean ± standard 268 
deviation. Statistical significance was determined via GraphPad prism t-test. In all 269 
cases, a P value less than 0.05 were considered to be statistically significant. 270 
Parametric data was analysed using one-way analysis of variance (ANOVA) 271 
followed by Tukey’s multiple comparisons test. Non-parametric data was analysed 272 
using the Kruskal-Wallis one way ANOVA followed by Dunn’s multiple comparisons 273 
test. Asterisks rating of *, **, *** or **** indicates statistically significant differences 274 
between groups (P≤0.05, P≤0.01, P≤0.001, P≤0.0001, respectively).  275 
 276 
3. Results 277 
 278 
 279 
3.1 Minimum inhibitory concentration assays 280 
 281 
Nisin V and nisin S29A are previously generated nisin derivatives that exhibit 282 
enhanced activity against a number of targets arising from single amino acid 283 
alterations (Fig. 1) (Field et al., 2012). These peptides and nisin A were purified and, 284 
following purification and freeze-drying, mass spectrometry analysis was performed. 285 
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Peptide masses of 3,321 Da, 3,336 Da and 3,353 Da were obtained for nisin peptides 286 
V, S29A and nisin A as expected (data not shown). To more accurately quantify the 287 
specific activity of the peptides, broth-based MIC determination assays were carried 288 
out using purified peptides against the chosen Gram negative targets (Table 2). Nisin 289 
S29A exhibited two-fold greater specific activity than nisin A against E. coli O157:H7 290 
TUV 93-0::p16Slux-Phelp (3.75 μM and 7.5 μM, respectively) and C. sakazakii NCTC 291 
8155::p16Slux-Phelp (1.87 μM and 3.75 μM, respectively). In the case of nisin V, 292 
enhanced specific activity compared to nisin A was observed for E. coli O157:H7 TUV 293 
93-0::p16Slux-Phelp (3.75 μM and 7.5 μM, respectively) but activity was equal to that 294 
of nisin A when examined against C. sakazakii NCTC 8155::p16Slux-Phelp.  These 295 
results demonstrate for the first time the enhanced activity of nisin V against a 296 
Gram-negative strain (E. coli O157:H7 TUV 93-0::p16Slux-Phelp) in a broth-based MIC 297 
assay. The enhanced efficacy of S29A compared to nisin A against some Gram 298 
negative strains has previously been reported (Field et al., 2012).  299 
The susceptibility of the Gram-negative strains to the essential oils thymol, 300 
carvacrol and trans-cinnamaldehyde was also assessed in order to ascertain 301 
appropriate concentrations for combinatorial assays (Table 2). The essential oils 302 
were found to be inhibitory at a concentration of 250 µg ml
-1
 against E. coli O157:H7 303 
TUV 93-0::p16Slux-Phelp and C. sakazakii NCTC 8155::p16Slux-Phelp, with the 304 
exception that thymol prevented the growth of C. sakazakii NCTC 8155::p16Slux-Phelp 305 
at a concentration of 125 µg ml
-1
. These values are consistent with those previously 306 
reported (Hyldgaard et al., 2012). 307 
 308 
3.2 Growth and kill-curve assays 309 
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 310 
Having shown the increased specific activity of the nisin variants against C. 311 
sakazakii NCTC 8155::p16Slux-Phelp and E. coli O157:H7 TUV 93-0::p16Slux-Phelp, a 312 
more detailed investigation of the impact of the nisin peptides alone, and in 313 
combination with essential oils, on bacterial growth was examined. Due to relatively 314 
large inoculum (10
7
 cfu ml
-1
) employed for growth curve analysis, the impact of 315 
concentrations of 30 µM and 15 µM nisin peptides against C. sakazakii NCTC 316 
8155::p16Slux-Phelp and E. coli O157:H7 TUV 93-0::p16Slux-Phelp, respectively, was 317 
tested along with varying concentrations (75-200 µg ml
-1
) of essential oils. When 318 
nisin V was used in combination with 100 µg ml
-1
 thymol and 125 µg ml
-1
 carvacrol or 319 
trans-cinnamaldehyde, a more profound delay in growth was observed compared to 320 
that of either treatment alone against C. sakazakii NCTC 8155::p16Slux-Phelp (Figs. 2). 321 
Nisin S29A-essential oil combinations were also better than their nisin A-essential oil 322 
equivalents (Fig. 2). However, statistically significant differences in bacterial 323 
inhibition were recorded only when nisin variants (V and S29A) were used in 324 
combination with the essential oil carvacrol and trans-cinnamaldhyde (Figs. 2C; P-325 
value = 0.0209, 2E; P-value = 0.0007 and 2F; P-value =0.0014), as compared to the 326 
nisin variant used alone. No significant difference in bacterial inhibition was 327 
observed for nisin variants in combination with thymol (Fig. 2A; P-value =0.0681 and 328 
2B; P-value =0.5645). Growth curves with E. coli O157:H7 TUV 93-0::p16Slux-Phelp 329 
show that combinations of nisin V and thymol (100 µg ml
-1
) or carvacrol (200 µg ml
-1
) 330 
result in a longer lag phase than when either treatment is used singly (Figs. 3A and 331 
3C). A similar pattern was observed when nisin S29A was used in combination with 332 
thymol or carvacrol (Figs. 3B and 3D). Indeed, statistically significant differences in 333 
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bacterial inhibition were recorded when nisin variants (V and S29A) used in 334 
combination with the essential oils thymol and carvocrol (Figs. 3A; P-value =0.0022, 335 
3B; P-value = 0.0176, 3C; P-value =0.0029 and 3D; P-value = 0.0001), as compared to 336 
the nisin variant used alone. No significant difference in lag time was observed for 337 
nisin variants in combination with 75 µg ml
-1
 trans-cinnamaldehyde (Fig. 3E; P-value 338 
=0.9675 and 3F; P-value =0.4427). Ultimately, the most significant delay in growth 339 
was observed when nisin V and carvacrol were combined against E. coli O157:H7 340 
TUV 93-0::p16Slux-Phelp (Fig. 3C). Overall, it was apparent that, in general, the use of 341 
nisin V or nisin S29A resulted in greater inhibitory effects on growth than was 342 
observed when nisin A alone was used, and this phenomenon was also apparent 343 
when the bacteriocins were used together with essential oils. 344 
Following on from this, the bactericidal activities of nisin peptides and 345 
essential oils against the Gram negative pathogens were investigated through kill 346 
curve analysis. C. sakazakii NCTC 8155::p16Slux-Phelp and E. coli O157:H7 TUV 93-347 
0::p16Slux-Phelp were treated respectively with 60 µM and 30 µM of each nisin 348 
peptide in combination with 150 µg ml
-1
 thymol, 300 µg ml
-1
 carvacrol or 350 µg ml
-1
 349 
trans-cinnamaldehyde (Figs. 4 and 5). In general, an approximate 1-log reduction in 350 
pathogen cell numbers were observed when either nisin peptides or essential oils 351 
were used alone, with the exception that carvacrol and trans-cinnamaldehyde had 352 
no effect against C. sakazakii NCTC 8155::p16Slux-Phelp (Figs. 4B and 4C, respectively) 353 
and the use of thymol alone against E. coli O157:H7 TUV 93-0::p16Slux-Phelp resulted 354 
in an approximate 3.5-log reduction in cell numbers (Fig. 5A). The killing effect of 355 
nisin peptides was more marked by the addition of essential oils. The antimicrobial 356 
activity of nisin peptides was significantly enhanced when used in combination with 357 
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thymol (~2-log reduction), carvacrol (~4-log reduction) and trans-cinnamaldehyde 358 
(~1.5-log reduction) against C. sakazakii NCTC 8155::p16Slux-Phelp (Fig. 4). A similar 359 
significant level of inactivation of E. coli O157:H7 TUV 93-0::p16Slux-Phelp was 360 
achieved when thymol (~4.5-log reduction), carvacrol (~3-log reduction) and trans-361 
cinnamaldehyde (~2-log reduction) were used in combination with nisin peptides 362 
(Fig. 5). It was also established that the use of bioengineered nisin derivatives in 363 
combination with essential oils was more effective than nisin A-essential oil 364 
combinations. A significantly greater reduction in E. coli O157:H7 TUV 93-0::p16Slux-365 
Phelp was observed when thymol was used in combination with nisin V or nisin S29A, 366 
rather than nisin A (P<0.05) (Fig. 5A). A similar observation was made when trans-367 
cinnamaldehyde and C. sakazakii NCTC 8155::p16Slux-Phelp were utilised, in that a 368 
considerable reduction in viable cell numbers was observed when the essential oil 369 
was used in conjunction with nisin V (Fig. 4C). Furthermore, an increased bactericidal 370 
activity was seen when combinations of nisin V and nisin S29A with carvacrol were 371 
used, resulting in a 2-log greater reduction in C. sakazakii NCTC 8155::p16Slux-Phelp 372 
cell counts than was the case when a nisin A-carvacrol combination was used (Fig. 373 
4B). 374 
 375 
3.4 Model food trials 376 
  377 
Having shown the enhanced potency of bioengineered nisin variants in 378 
combination with carvacrol against both Gram negative pathogens using kill curve 379 
assays, this essential oil was selected for further investigation in model food systems. 380 
To this end, commercially available powdered infant formula milk and commercially 381 
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produced apple juice were chosen as they have been associated with disease 382 
outbreaks of C. sakazakii and E. coli O157:H7, respectively. For the powdered infant 383 
formula milk studies, nisin A, nisin V or nisin S29A (60 µM) were added alone or in 384 
combination with carvacrol (300 µg ml
-1
) (Fig. 6A). The addition of carvacrol did not 385 
significantly alter the pH.  The milk was subsequently spiked with C. sakazakii NCTC 386 
8155::p16Slux-Phelp at a concentration of 1 × 10
5
 cfu ml
-1
 and incubated at room 387 
temperature for 3 h. Serial dilution and subsequent plate counts revealed that nisin 388 
and/or essential oil treatment had no effect on C. sakazakii NCTC 8155::p16Slux-389 
Phelp, as cell numbers remained unaltered (Fig 6A). It was noted, however, that the 390 
addition of the food-grade antimicrobial, citric acid (30 mM) reduced viable cell 391 
numbers of C. sakazakii NCTC 8155::p16Slux-Phelp (~0.5-log reduction) while 392 
combinations of nisin and citric acid resulted in a significant decrease of C. sakazakii 393 
NCTC 8155::p16Slux-Phelp cell numbers (1-log reduction) compared to nisin usage 394 
alone (P<0.001) (Fig. 6B). Combinations of all three antimicrobials improved 395 
antibacterial activity relative to nisin and the essential oil carvacrol. While there was 396 
a numerical improvement in activity relative to that of citric acid, this was not 397 
significant (Fig. 6C). Additionally, nisin variant combinations did not display an 398 
enhanced potency compared to the equivalent nisin A combined treatment.  399 
Given that the essential oil/nisin combinations did not significantly enhance 400 
the efficacy of citric acid against C. sakazakii NCTC 8155::p16Slux-Phelp in infant 401 
formula, we investigated the possibility that another nisin-based, food grade 402 
formulation could prove to be effective. For this purpose Nisaplin, a commercial 403 
formulation containing nisin A was used together with citric acid. Notably, this 404 
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combination brought about a significant >3-log reduction in bacterial cell counts (Fig. 405 
7). This effect was not further augmented through the addition of carvacrol.  406 
The commercially produced apple juice was filtered and the pH measured. 407 
Nisin A, nisin V or nisin S29A (30 µM) was added to the juice alone or in combination 408 
with low level of carvacrol (75 µg ml
-1
) before E. coli O157:H7 TUV 93-0::p16Slux-Phelp 409 
was introduced at a concentration of 1 × 10
5  
cfu ml
-1
. Following incubation for 3 h at 410 
room temperature, serial dilutions and plate counts on Sorbitol MacConkey agar 411 
were carried out to enumerate bacterial cell counts. When nisin A, nisin V, nisin S29A 412 
or carvacrol were used alone, an approximate 1-log reduction in E. coli O157:H7 TUV 413 
93-0::p16Slux-Phelp cell numbers were obtained. The effectiveness of nisin A was 414 
significantly improved when used in conjunction with carvacrol, resulting in a 2.5-log 415 
reduction in cells counts compared to that of the initial inoculum. Notably, the 416 
combinations of nisin V and nisin S29A with carvacrol were even more effective in 417 
that a 3-log reduction in bacterial cell counts was attained over the 3 h period (Fig. 418 
8). More importantly, these results demonstrate that the enhanced effectiveness of 419 
nisin variants observed using laboratory-based assays are retained and can be 420 
translated to food systems.  421 
 422 
4. Discussion 423 
 424 
It has previously been reported that the phenolic compounds carvacrol and 425 
thymol have the ability to degrade the outer membranes of the Gram negative 426 
bacteria, E. coli and Salmonella Typhimurium (Helander et al., 1998). This 427 
phenomenon likely explains why exposure to these compounds increases the 428 
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sensitivity of C. sakazakii NCTC 8155::p16Slux-Phelp and E. coli O157:H7 TUV 93-429 
0::p16Slux-Phelp to nisin. Our investigations also highlight the enhanced potency of 430 
nisin when combined with trans-cinnamaldehyde. In the latter case, the mechanism 431 
involved may be different as trans-cinnamaldehyde does not disintegrate the outer 432 
membrane like carvacrol and thymol, but is believed that at sub-inhibitory 433 
concentrations, inhibits the activity of trans-membrane ATPase (Gill and Holley, 434 
2006a, b).   435 
This study also demonstrates the frequently superior activity of 436 
bioengineered nisin variants over their wild type nisin A equivalent when used in 437 
combination with a variety of essential oils. In growth curve assays, nisin V-essential 438 
oil and nisin S29A-esssential oil combinations, except when combined with trans-439 
cinnamaldehyde against E. coli O157:H7 TUV 93-0::p16Slux-Phelp, surpassed the 440 
activity of their nisin A counterparts as observed by the longer delay in growth. With 441 
respect to time-kill assays, nisin variant-combinations outperformed their 442 
corresponding nisin A-combinations by at least 1-log reduction in cell numbers 443 
against C. sakazakii NCTC 8155::p16Slux-Phelp (carvacrol and trans-cinnamaldehyde) 444 
and E. coli O157:H7 TUV 93-0::p16Slux-Phelp (thymol and carvacrol). This increased 445 
effectiveness did not translate into powdered infant formula milk (Fig. 6A). It is 446 
known that the greater availability of nutrients in foods compared to laboratory 447 
media may enable bacterial cells to repair damaged cells faster (Gill et al., 2002). As 448 
a consequence of this protective nature, a greater concentration (approximately 449 
two-fold) of essential oils are required to achieve the same effect in foods, such as 450 
semi-skimmed milk (Karatzas et al., 2001). Instead of increasing concentrations of 451 
carvacrol and potentially altering the sensory properties of the infant milk formula, 452 
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the preservative citric acid (30 mM) was incorporated. A significant reduction (1-log) 453 
in bacterial counts was observed when nisin and citric acid were used simultaneously 454 
compared to nisin alone (Fig. 6B). However, the combination of all three 455 
antimicrobial agents did not improve significantly on the activity of citric acid against 456 
C. sakazakii NCTC 8155::p16Slux-Phelp (Fig. 6C). The substitution of nisin peptides for 457 
food-grade Nisaplin (10 mg ml
-1
) proved most effective as >3-log reduction in C. 458 
sakazakii NCTC 8155::p16Slux-Phelp cell counts was observed after treatment with 459 
Nisaplin and citric acid (Fig. 7). Nisaplin contains 2.5% active nisin and the remainder 460 
is made up of a balance of sodium chloride and denatured milk solids. The high 461 
percentage of salts present is likely to contribute to antimicrobial activity. The nisin-462 
containing formulation was employed as it is commercially available and approved 463 
for use in over 50 countries worldwide. Should equivalent forms of nisin V/S29A be 464 
generated, there is the potential for these peptides to be used in the same way with 465 
the possibility of even greater antimicrobial efficacy. 466 
Due to the demand for minimally processed foods, researchers have 467 
previously investigated the use of natural antimicrobials including nisin and 468 
cinnamon in apple juice (Yuste and Fung, 2004). In this study, we also investigated 469 
the merits of using nisin in combination with the essential oil carvacrol in apple juice. 470 
The combination of the bioengineered nisin variants with carvacrol accelerated 471 
bacterial death, resulting in a >3-log reduction in E. coli O157:H7 TUV 93-0::p16Slux-472 
Phelp cell counts after 3 h (Fig. 8). The low pH of the apple juice may partially 473 
contribute to this effect. It is also known that essential oils are most effective at 474 
acidic pHs (Burt, 2004) due to the increase in hydrophobicity and better diffusion 475 
into the lipid phase of the membrane (Juven et al., 1994). Moreover, nisin is more 476 
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stable at acidic pH and therefore more effective (Delves-Broughton, 1990). While, 477 
the manufacture of fruit juices should include effective treatments so as to result in 478 
a cumulative 5-log reduction in the numbers of E. coli O157:H7 as specified by the 479 
Food and Drug Administration’s Guidance for Industry (FDA, 2001), the detection 480 
limit in this study was 10
2
 cfu ml
-1
 and thus the use of more sensitive detection 481 
methods may reveal that this cumulative reduction can be achieved.  482 
The use of essential oils in foods has been limited due to the high 483 
concentrations required to achieve sufficient antimicrobial activity (Hyldgaard et al., 484 
2012). Notably, however, this study shows that relatively low concentrations of 485 
carvacrol (approximately 0.0075%) could be used in combination with nisin to inhibit 486 
E. coli O157:H7 TUV 93-0::p16Slux-Phelp in apple juice. Before commercial 487 
application, sensory studies would have to be carried out to determine the 488 
organoleptic properties of apple juice with essential oils. Although, upon addition of 489 
such a low concentration of carvacrol in this study, no adverse aroma was observed. 490 
Recently, sensory evaluations were carried out to assess the consequence of adding 491 
75 µl L
-1
 (~63.75 µg ml
-1
) of lemon essential oil to apple juice. Researchers found that 492 
this relatively small concentration of essential oil did not decrease the acceptability 493 
of the sample or the organoleptic properties (Espina et al., 2012). Moreover, all of 494 
the tested essential oils have GRAS status by both the EU and the FDA (EU, 2012; 495 
FDA, Revised 2014a, b) meaning that their addition could be permitted if they were 496 
used in the minimum quantities and with good manufacturing processes. 497 
 498 
5. Conclusion 499 
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The combination of nisin peptides and essential oils could pave the way for 500 
new hurdle concepts when it comes to food preservation, in particular towards 501 
Gram negative bacteria. Moreover, the combinatory effects could lead to reduced 502 
treatment intensity and/or antimicrobial dosage and therefore avoid undesirable 503 
sensory and nutritional properties in food. Such combinations could enhance food 504 
safety, shelf life and quality while also meeting consumer demands for more natural, 505 
preservative-free foods.  506 
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 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
 698 
Tables 699 
 700 
Strains/Lux-tagged bacteria Relevant characteristics or source 
of strains 
Reference 
Lactococcus lactis NZ9700 Wild-type nisin producer (Kuipers et al., 1993; 
Kuipers et al., 1998) 
Lactococcus lactis NZ9800 L. lactis NZ9700ΔnisA (Kuipers et al., 1993; 
Kuipers et al., 1998) 
Lactococcus lactis NZ9800 
pCI372nisA 
Wild-type nisin-producing strain (Field et al., 2008) 
Lactococcus lactis NZ9800 
pCI372nisA::M21V 
Wild-type producing strain + 
alteration at position 21 
(Field et al., 2010) 
Lactococcus lactis NZ9800 
pCI372nisA::S29A 
Wild-type nisin-producing strain + 
alteration at position 29 
(Field et al., 2012) 
Cronobacter sakazakii NCTC 
8155::p16Slux-Phelp 
Isolated from dried milk powder and 
transformed with p16Slux-Phelp 
plasmid 
UCC Culture 
Collection 
Escherichia coli O157:H7 TUV 
93-0::p16Slux-Phelp 
Derived from strain EDL933 and 
transformed with p16Slux-Phelp 
UCC Culture 
Collection 
 701 
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List of nisin-producing strains and lux-tagged bacterial strains used in this study, 703 
including relevant characteristics and references. 704 
 705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
 714 
 715 
 716 
Table 2  717 
Minimum inhibitory concentration determinations of nisin A, nisin V, nisin S29A and 718 
the essential oils thymol, carvacrol and trans-cinnamaldehyde against C. sakazakii 719 
NCTC 8155::p16Slux-Phelp and E. coli O157:H7 TUV 93-0::p16Slux-Phelp. Results are 720 
expressed as the mean of triplicate assays. Values in bold represent statistical 721 
difference between nisin variants and wild type nisin A (Student’s t-test: P<0.05). 722 
Indicator 
organism 
Nisin A 
μg ml
-1
 (µM) 
Nisin V 
μg ml
-1
 (µM) 
Nisin S29A 
μg ml
-1
 (µM) 
Thymol 
μg ml
-1
 
Carvacrol 
μg ml
-1
 
Cinnamalde
-hyde 
μg ml
-1
 
C. sakazakii NCTC 
8155::p16Slux-Phelp 
12.57 (3.75) 12.57 (3.75) 6.28 (1.875) 
(P<0.001) 
125 250 250 
E. coli O157:H7 
TUV 93-
0::p16Slux-Phelp 
25.14 (7.5) 12.57 (3.75) 
(P<0.001) 
12.57 (3.75) 
(P<0.001) 
250 250 250 
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 731 
 732 
 733 
 734 
 735 
Figure legends 736 
 737 
Fig. 1. Structure and mass spectrometry analysis of nisin A and its derivatives. (A) 738 
Structural composition of nisin A. Blue circles indicate where amino acids were 739 
altered resulting in the generation of nisin variants with enhanced activity.  740 
 741 
Figure 2. Growth curve analysis of C. sakazakii NCTC8155::p16Slux-Phelp with 30μM 742 
nisin A (open square), (A) nisin V (open diamond), 100μg/ml thymol (open circle) and 743 
combinations of nisin A and thymol (closed square), nisin V and thymol (closed 744 
diamond) (B) nisin S29A (open inverted triangle), 100μg/ml thymol (open circle) and 745 
combinations of nisin A and thymol (closed square), nisin S29A and thymol (closed 746 
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inverted triangle). (C) nisin V (open diamond), 125μg/ml carvacrol (open circle) and 747 
combinations of nisin A and carvacrol (closed square), nisin V and carvacrol (closed 748 
diamond) (D) nisin V (open diamond), nisin S29A (open inverted triangle), 125μg/ml 749 
carvacrol (open circle) and combinations of nisin A and carvacrol (closed square) and 750 
nisin S29A and thymol (closed inverted triangle). (E) nisin V (open diamond), 751 
125μg/ml trans-cinnamaldehyde (open circle) and  combinations of nisin A and 752 
trans-cinnamaldehyde (closed square), nisin V and trans-cinnamaldehyde (closed 753 
diamond) (F) nisin S29A (open inverted triangle), 125μg/ml trans-cinnamaldehyde 754 
(open circle) and  combinations of nisin A and trans-cinnamaldehyde (closed 755 
square)and nisin S29A and trans-cinnamaldehyde (closed inverted triangle).  756 
 757 
Figure 3. Growth curve analysis of E. coli O157:H7 TUV93-0::p16Slux-Phelp with 30μM 758 
nisin A (open square), (A) nisin V (open diamond), 100μg/ml thymol (open circle) and 759 
combinations of nisin A and thymol (closed square), nisin V and thymol (closed 760 
diamond) (B) nisin S29A (open inverted triangle), 100μg/ml thymol (open circle) and 761 
combinations of nisin A and thymol (closed square), nisin S29A and thymol (closed 762 
inverted triangle). (C) nisin V (open diamond), 125μg/ml carvacrol (open circle) and 763 
combinations of nisin A and carvacrol (closed square), nisin V and carvacrol (closed 764 
diamond) (D) nisin V (open diamond), nisin S29A (open inverted triangle), 125μg/ml 765 
carvacrol (open circle) and combinations of nisin A and carvacrol (closed square) and 766 
nisin S29A and thymol (closed inverted triangle). (E) nisin V (open diamond), 767 
125μg/ml trans-cinnamaldehyde (open circle) and  combinations of nisin A and 768 
trans-cinnamaldehyde (closed square), nisin V and trans-cinnamaldehyde (closed 769 
diamond) (F) nisin S29A (open inverted triangle), 125μg/ml trans-cinnamaldehyde 770 
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(open circle) and  combinations of nisin A and trans-cinnamaldehyde (closed 771 
square)and nisin S29A and trans-cinnamaldehyde (closed inverted triangle).  772 
 773 
Fig. 4. Kill effect of nisin A derivatives in combination with essential oils against C. 774 
sakazakii NCTC 8155::p16Slux-Phelp. Kill curve analysis of C. sakazakii NCTC 775 
8155::p16Slux-Phelp with 60 μM of each peptide both alone and in combination with 776 
(A) 150 μg ml
-1
 thymol (THY), (B) 300 μg ml
-1
 carvacrol (CA) and (C) 350 μg ml
-1
 trans-777 
cinnamaldehyde (CN) in LB broth after 3 hours at room temperature.  778 
 779 
Fig. 5. Kill effect of nisin A derivatives in combination with essential oils against E. coli 780 
O157:H7 TUV 93-0::p16Slux-Phelp. Kill curve analysis of E. coli O157:H7 TUV 93-781 
0::p16Slux-Phelp with 30 μM of each nisin peptide both alone and in combination with 782 
(A) 150 μg ml
-1
 thymol (THY), (B) 300 μg ml
-1
 carvacrol (CA) and (C) 350 μg ml
-1
 trans-783 
cinnamaldehyde (CN) in LB broth after 3 hours at room temperature. ND, not 784 
detected. 785 
 786 
Fig. 6. Combinations of nisin derivatives, carvacrol and citric acid against C. sakazakii 787 
NCTC 8155::p16Slux-Phelp in powdered infant milk formula. Model food analysis of C. 788 
sakazakii NCTC 8155::p16Slux-Phelp in powdered infant milk formula with 60 µM of 789 
each nisin peptide both alone and in combination with (A) 300 µg ml
-1
 carvacrol (CA), 790 
(B) 30 mM citric acid (CT) and (C) 300 μg ml
-1
 carvacrol and 30 mM citric acid after 3 791 
hours at room temperature. 792 
 793 
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Fig. 7. Combinations of commercial Nisaplin, carvacrol and citric acid against C. 794 
sakazakii NCTC 8155::p16Slux-Phelp in powdered infant milk formula. Model food 795 
analysis of C. sakazakii NCTC 8155::p16Slux-Phelp in powdered infant milk formula 796 
with 10 mg ml
-1
 of commercial Nisaplin (Sigma) containing 2.5% nisin both alone and 797 
in combination with 300 µg ml
-1
 carvacrol (CA) and 30 mM citric acid (CT) after 3 798 
hours at room temperature. ND, not detected (detection limit of 10
2
 cfu ml
-1
).  799 
 800 
 801 
Fig. 8. Combinations of nisin A derivatives and carvacrol against E. coli O157:H7 TUV 802 
93-0::p16Slux-Phelp in apple juice. Model food analysis of E. coli O157:H7 TUV 93-803 
0::p16Slux-Phelp in apple juice with 30 µM of each nisin peptide both alone and in 804 
combination with 75 µg ml
-1
 carvacrol (CA) after 3 hours at room temperature. ND, 805 
not detected (detection limit of 10
2
 cfu ml
-1
). 806 
 807 
 808 
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